Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Michael J. Jelinek"'
Autor:
Mohamed F. Mohamed, Samer Al-Khudari, Puebla Cassini-Vieira, Amani Erra, Reem Bagabas, Thomas Houser, Kerstin Stenson, Mihir Bhayani, Michael J. Jelinek, Faraz Bishehsari, Timothy M. Kuzel, Sasha H. Shafikhani
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-8 (2022)
Abstract Recently, we described a phenomenon whereby apoptotic cells generate and release CrkI-containing microvesicles, which stimulate proliferation in surrounding cells upon contact to compensate for their own demise. We termed these microvesicles
Externí odkaz:
https://doaj.org/article/7fc7719325f246d987f6ab8b67d119df
Publikováno v:
Current Treatment Options in Oncology. 24:680-692
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af19e62e3b16a5716f96f3fbb8c4a76a
https://doi.org/10.1007/s11864-023-01080-5
https://doi.org/10.1007/s11864-023-01080-5
Autor:
Kevin, King, Ryan, Rauch, Soumyajit, Roy, Oleg, Menyok, Ken, Tatebe, Bobby, Tajudeen, Peter, Papagiannopoulos, Pete S, Batra, Mihir, Bhayani, Samer, Al-Khudari, Kirsten, Stenson, Michael J, Jelinek, Mary Jo, Fidler, Nikhil, Joshi
Publikováno v:
Anticancer Research. 42:5449-5455
There is significant variation in post-treatment surveillance imaging for sinonasal malignancies. This study examined the utility of surveillance imaging in detecting recurrence in patients treated for sinonasal malignancies.We performed a retrospect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef131e59b6ef0fefbc1003e9fc928723
https://doi.org/10.21873/anticanres.16049
https://doi.org/10.21873/anticanres.16049
Autor:
Michael J. Jelinek, Charu Aggarwal
Publikováno v:
Oncologist
Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), is the new first line standard of care in metastatic non-small cell lung cancer (NSCLC) based on improvements in overall survival (OS), control of central nervous system (CNS) dise
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c516b910b882b77efde6613b41a26e0f
https://doi.org/10.1002/onco.13634
https://doi.org/10.1002/onco.13634
Autor:
Michael J. Jelinek, Christine M. Bestvina, Septimiu Murgu, Hania A. Al-Hallaq, J.M. Melotek, Aditya Juloori, J. Partouche, Theodore Karrison, Sean P. Pitroda, Everett E. Vokes, Philip C. Hoffman, Ralph R. Weichselbaum, K.B. Pointer, Jyoti D. Patel, Steven J. Chmura
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 17(1)
Previous studies have evaluated stereotactic body radiotherapy (SBRT) in oligometastatic patients with NSCLC, including multimodality treatment with anti-programmed cell death protein-1 monotherapy. Questions remain regarding the timing of SBRT and i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43d4daec3052336c735097be28a672df
https://pubmed.ncbi.nlm.nih.gov/34500113
https://pubmed.ncbi.nlm.nih.gov/34500113
Autor:
Everett E. Vokes, Tanguy Y. Seiwert, Michael J. Jelinek, Alex J. Zoroufy, Pamela N. Munster, Gary K. Schwartz, Jonas A. De Souza, Nathan R. Foster
Publikováno v:
Oral Oncol
ObjectivesWe report the results of this phase I study to evaluate the maximum tolerated dose (MTD) and safety of veliparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, combined with carboplatin and paclitaxel induction chemotherapy (IC) for locor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3727d3b6e9021f6e5e3e12738442db5e
https://europepmc.org/articles/PMC7933088/
https://europepmc.org/articles/PMC7933088/
Publikováno v:
Journal of Oncology Practice. 14:541-546
Head and neck squamous cell carcinoma (HNSCC) frequently affects elderly patients. Given the frailty and comorbid conditions of this population as well as the potential toxicities associated with treatment, there is a risk of undertreatment in older
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6419a06cb471427616bc7c96ffcb8c1
https://doi.org/10.1200/jop.18.00078
https://doi.org/10.1200/jop.18.00078
Autor:
Michael J. Jelinek, Walter M. Stadler, Jay L. Koyner, Alicia Wyche Okpareke, Peter H. O’ Donnell, Patrick T. Murray, Sang Mee Lee, Claudia Wing
Publikováno v:
Clinical and Translational Science. 11:420-427
Acute kidney injury (AKI) limits cisplatin use. We tested whether urine cystatin C (uCyC) and neutrophil gelatinase-associated lipocalin (uNGAL) can preidentify patients at risk for AKI. Patients initiating cisplatin-based chemotherapy were prospecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::118dcf2ab244b2a6436d777cdb280dad
https://doi.org/10.1111/cts.12547
https://doi.org/10.1111/cts.12547
Autor:
Everett E. Vokes, Michael J. Jelinek
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37(31)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62ed5d0cc75ff0d44490494da13aef38
https://pubmed.ncbi.nlm.nih.gov/31483688
https://pubmed.ncbi.nlm.nih.gov/31483688
Publikováno v:
Clinical lung cancer. 20(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9b97c783b5eeedde78fb6b6eb502757
https://pubmed.ncbi.nlm.nih.gov/31542322
https://pubmed.ncbi.nlm.nih.gov/31542322